The company’s stock dropped after details of a study raised questions about how widely the treatment would be used.

Moderna fell after leaked phase 3 cancer vaccine data sparked debate on melanoma benefit, approval odds, and uptake risks.

The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...

Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 ...

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/Getty. A ...

Moderna shares are taking a hit after the leak of highly anticipated details about the company’s vaccine for the skin cancer ...

A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return ...

Biotech company Moderna ($MRNA) saw its shares fall by as much as 25% on Thursday, October 22, despite positive results from ...

Moderna has delivered a very large gain over the past year, even after a sharp recent pullback. This puts fresh attention on whether its current share price is supported by the sales investors are ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...

Why Moderna stock sank 17% after leaked cancer vaccine data, as investors weighed incomplete Phase 3 results, valuation risks ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...